Author/Authors :
Biswanath Kundu، نويسنده , , Debasree Ghosh، نويسنده , , Mithlesh Kumar Sinha، نويسنده , , Partha Sarathi Sen، نويسنده , , Vamsi Krishna Balla، نويسنده , , Nirmalendu Das، نويسنده , , Debabrata Basu، نويسنده ,
Abstract :
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide, and satisfactory treatment is unavailable. Doxorubicin (DOX) is commonly used for HCC treatment with very limited success and serious side-effects such as cardiotoxicity and non-cancer cell cytotoxicity.
Keywords :
Nano-hydroxyapatite , hepatocellular carcinoma , doxorubicin , IN VIVO , HAp-DOX conjugate
